The FDA raised another safety flag over the continued off-label use of Avastin Wednesday when it issued a MedWatch alerting physicians of a recall of the compounded cancer drug intended as an unapproved treatment for wet age-related macular degeneration (AMD). While that's bad news for compounders, it could be good news for Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y.